# Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

> **NCT05304455** · NA · COMPLETED · sponsor: **Northern Jiangsu People's Hospital** · enrollment: 40 (actual)

## Conditions studied

- Cirrhosis
- Splenectomy
- Venous Thrombosis
- Hypertension, Portal

## Interventions

- **DRUG:** Apixaban 2.5 MG
- **DRUG:** Dipyridamole 25Mg Tab
- **DRUG:** subcutaneous Low Molecular Weight Heparin

## Key facts

- **NCT ID:** NCT05304455
- **Lead sponsor:** Northern Jiangsu People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304455, "Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05304455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*